Clinical Research Directory

Inclusion Criteria: * Inclusion criteria * Adult patients (\>18 years old). * Patients with confirmed diagnosis of non-metastatic breast cancer planned to receive weekly adjuvant/neo-adjuvant paclitaxel. * Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 Exclusion criteria * Patients with pre-existing neuropathic conditions. * Patients with diabetes mellitus. * Patients with a history of seizure disorder. * Patients with renal impairment (creatinine clearance less than 60 ml/min), or hepatic impairment (defined as ALT an AST \> 3 times upper limits of normal) * Patients with inadequate bone marrow functions (defined as absolute neutrophilic count less than 1,500/mm³ or platelets count less than 100,000/mm³). * Concomitant use of vitamin B1, B6, B9, or B12. * Patients receiving medications that possibly induce peripheral neuropathy including amiodarone, colchicine, metronidazole, antimycobacterials, and nucleoside reverse transcriptase inhibitors, and phenytoin (Jones et al., 2020). * Patients receiving gabapentinoids, antidepressants, or opioids. * Pregnancy or lactation. * History of hypersensitivity to amantadine * Concurrent use of anticholinergic drugs (e.g., antihistamines, tricyclic antidepressants, antipsychotics, antispasmodics, or antiparkinsonian agents) within 2 weeks before enrollment, except for short-term use of antiemetics prescribed as part of standard chemotherapy supportive care (e.g., prochlorperazine, promethazine). Exclusion Criteria: \-